Premier Biomedical has announced successful advances in cancer-focused research. The company’s researchers have successfully killed a cancer tumor in a test tube by simply removing crucial molecular compounds that are necessary for the cancer’s development. They accomplished this by utilizing the Felder Doctrine, which states: “Physically remove the pathophysiologic basis of the disease.”
Currently used methods for treating cancer, like chemotherapy and many conventional cancer-fighting drugs, are able to target only one single antigen, which permits another antigen to survive the treatment and allows the cancer to progress. Additionally, these blockers or inhibitors are frequently accompanied by dangerous side effects for patients. Premier Biomedical’s focus is to aim for far greater efficiency through simultaneously mixing and matching multiple cancer target antigens. The company actually removes the disease’s pathophysiologic basis – targeting the precise cause of the disease and eliminating it without dangerous side effects.
Premier Biomedical’s researchers have specifically removed a particular cancer-related Interleukin from a heterogeneous mixture at a pictogram (trillionth of a gram) level of accuracy. This can potentially open the door to a methodology for eradicating cancer tissue without using any other medications and/or procedures, which are often accompanied by related side effects. Additional testing has resulted in the successful removal of additional critical cancer-related antigens that are important to the development, growth, and metastasis of cancer tissue. The focuses of these recent successes were leukemia and lymphoma cancers.
Premier Biomedical is a research-based company operating on the intent of discovering and developing medical treatments for humans – specifically targeting the treatment of Alzheimer’s disease, fibromyalgia, multiple sclerosis, traumatic brain injury, amyotrophic lateral sclerosis (ALS/Lou Gehrig’s Disease), blood sepsis and viremia, and cancer. The company has licensed the technology behind various provisional patents in the U.S. and a PCT Europe National Patent in the areas of cancer, sepsis, and MS. Premier was founded in 2010 and is headquartered in Florida, with offices in Pennsylvania.
For more information, visit www.premierbiomedicalinc.com
Let us hear your thoughts below: